MA52555A - Modulateurs du récepteur des oestrogènes - Google Patents

Modulateurs du récepteur des oestrogènes

Info

Publication number
MA52555A
MA52555A MA052555A MA52555A MA52555A MA 52555 A MA52555 A MA 52555A MA 052555 A MA052555 A MA 052555A MA 52555 A MA52555 A MA 52555A MA 52555 A MA52555 A MA 52555A
Authority
MA
Morocco
Prior art keywords
eestrogen
receptor modulators
modulators
receptor
eestrogen receptor
Prior art date
Application number
MA052555A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Samantha Jayne HUGHES
Thomas Andrew MOSS
Johannes Wilhelmus Maria Nissink
James Stewart Scott
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA52555A publication Critical patent/MA52555A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA052555A 2017-01-30 2018-01-29 Modulateurs du récepteur des oestrogènes MA52555A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
MA52555A true MA52555A (fr) 2021-03-17

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052555A MA52555A (fr) 2017-01-30 2018-01-29 Modulateurs du récepteur des oestrogènes

Country Status (35)

Country Link
US (3) US10221173B2 (fr)
EP (2) EP3494116B1 (fr)
JP (1) JP6951451B2 (fr)
KR (1) KR102246668B1 (fr)
CN (1) CN110214140B (fr)
AU (1) AU2018211495B2 (fr)
CL (1) CL2019001991A1 (fr)
CO (1) CO2019008941A2 (fr)
CR (1) CR20190379A (fr)
CY (1) CY1122731T1 (fr)
DK (1) DK3494116T3 (fr)
DO (1) DOP2019000183A (fr)
EC (1) ECSP19062381A (fr)
ES (2) ES2766249T3 (fr)
HU (1) HUE047761T2 (fr)
IL (1) IL268263B (fr)
JO (1) JOP20190183B1 (fr)
LT (1) LT3494116T (fr)
MA (1) MA52555A (fr)
MX (1) MX2019008438A (fr)
MY (1) MY196317A (fr)
NI (1) NI201900080A (fr)
PE (1) PE20191500A1 (fr)
PH (1) PH12019501724A1 (fr)
PL (1) PL3494116T3 (fr)
PT (1) PT3494116T (fr)
RS (1) RS59770B1 (fr)
SG (1) SG11201906767XA (fr)
SI (1) SI3494116T1 (fr)
SM (1) SMT202000010T1 (fr)
TN (1) TN2020000009A1 (fr)
TW (1) TWI794205B (fr)
UA (1) UA125043C2 (fr)
WO (1) WO2018138303A1 (fr)
ZA (1) ZA201904696B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102479822B1 (ko) 2016-02-05 2022-12-21 인벤티스바이오 엘엘씨 선택적 에스트로겐 수용체 분해제 및 이들의 용도
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
EP1746157A4 (fr) * 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd Methode de proliferation de cellule plasmatique
WO2006101434A1 (fr) 2005-03-22 2006-09-28 Astrazeneca Ab Nouveaux derives de tetrahydro-1h-pyrido [4,3-b]indole utilises comme ligands du recepteur cb1'
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (fr) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
WO2010138659A1 (fr) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Procédés pour traiter des tumeurs cérébrales
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2010138695A1 (fr) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Procédés pour traiter la neurofibromatose
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
CA2915534A1 (fr) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Modulateurs azetidine des recepteurs d'oestrogenes et leurs utilisations
WO2015092634A1 (fr) 2013-12-16 2015-06-25 Novartis Ag Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
WO2016097071A1 (fr) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Modulateurs du récepteur des œstrogènes et leurs utilisations
WO2016174551A1 (fr) 2015-04-27 2016-11-03 Pfizer Inc. Composés anti-œstrogéniques
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
US10087191B2 (en) 2015-06-16 2018-10-02 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
HK1258851A1 (zh) 2015-11-09 2019-11-22 豪夫迈‧罗氏有限公司 四氢萘雌激素受体调节剂及其用途
JP6592197B2 (ja) 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
CA3006683A1 (fr) 2015-12-22 2017-06-29 Jiangsu Hengrui Medicine Co., Ltd. Derive de benzopiperidine, son procede de preparation et son utilisation medicale
EP3440067B1 (fr) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Modulateurs des récepteurs d' estrogènes tétrahydroisoquinoléine et leurs utilisations
WO2017182493A1 (fr) 2016-04-20 2017-10-26 Astrazeneca Ab Dérivés d'indazole destinés à être utilisés dans la régulation négative du récepteur d'œstrogène pour le traitement du cancer
US20190233442A1 (en) 2016-05-06 2019-08-01 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (fr) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 Dérivé à base d'acide acrylique, procédé de préparation s'y rapportant et utilisation médicale correspondante
US10149839B2 (en) * 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
EP3640251B1 (fr) 2016-10-24 2021-12-08 Astrazeneca AB Dérivés de 6,7,8,9-tétrahydro-3h-pyrazolo[4,3-f]isoquinoléine utiles dans le traitement du cancer
ES2941631T3 (es) 2016-12-16 2023-05-24 Lilly Co Eli Compuestos de Pirido[4,3-d][1,3]oxazin-2-ona como inhibidores de IDH1 e IDH2 mutantes
KR102314286B1 (ko) 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｊａｋファミリーのキナーゼの低分子阻害物質
EP3555050A1 (fr) 2016-12-16 2019-10-23 Basf Se Composés pesticides
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
GEP20207202B (en) 2017-01-30 2020-12-25 Chiesi Farm Spa Tyrosine amide derivatives as rho-kinase inhibitors

Also Published As

Publication number Publication date
PT3494116T (pt) 2020-01-28
MY196317A (en) 2023-03-24
EP3689873A1 (fr) 2020-08-05
JOP20190183A1 (ar) 2019-07-28
DK3494116T3 (da) 2020-01-27
TN2020000009A1 (en) 2021-10-04
PE20191500A1 (es) 2019-10-22
HUE047761T2 (hu) 2020-05-28
TWI794205B (zh) 2023-03-01
CA3050337A1 (fr) 2018-08-02
KR102246668B1 (ko) 2021-04-29
CO2019008941A2 (es) 2019-08-30
WO2018138303A1 (fr) 2018-08-02
PH12019501724A1 (en) 2020-06-01
US20190233413A1 (en) 2019-08-01
CR20190379A (es) 2019-10-21
IL268263B (en) 2021-10-31
ECSP19062381A (es) 2019-09-30
RS59770B1 (sr) 2020-02-28
US11046689B2 (en) 2021-06-29
CY1122731T1 (el) 2021-05-05
CN110214140A (zh) 2019-09-06
TW201840558A (zh) 2018-11-16
US20200239468A1 (en) 2020-07-30
NI201900080A (es) 2020-03-18
ZA201904696B (en) 2020-05-27
BR112019015389A2 (pt) 2020-03-10
US10221173B2 (en) 2019-03-05
US10590132B2 (en) 2020-03-17
EP3689873B1 (fr) 2022-09-14
ES2766249T3 (es) 2020-06-12
JP2020505354A (ja) 2020-02-20
IL268263A (en) 2019-09-26
ES2931320T3 (es) 2022-12-28
SMT202000010T1 (it) 2020-03-13
JP6951451B2 (ja) 2021-10-20
KR20190112767A (ko) 2019-10-07
US20180282325A1 (en) 2018-10-04
AU2018211495A1 (en) 2019-09-12
SI3494116T1 (sl) 2020-02-28
EP3494116A1 (fr) 2019-06-12
JOP20190183B1 (ar) 2022-09-15
UA125043C2 (uk) 2021-12-29
EP3494116B1 (fr) 2019-10-23
SG11201906767XA (en) 2019-08-27
DOP2019000183A (es) 2019-07-31
MX2019008438A (es) 2019-10-30
LT3494116T (lt) 2020-01-10
PL3494116T3 (pl) 2020-04-30
CN110214140B (zh) 2022-08-30
CL2019001991A1 (es) 2019-10-11
AU2018211495B2 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
MA43382A (fr) Modulateurs des récepteurs des chimiokines
EP3442971A4 (fr) Modulateurs du récepteur des estrogènes
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
DK3743406T3 (da) Tmem16a modulatorer
MA55328A (fr) Modulateurs de ror-gamma
DK3359160T3 (da) Farnesoid x receptor modulatorer
IL273830B2 (en) Aeroponics apparatus
MA53943A (fr) Modulateurs de ror-gamma
EP3521427A4 (fr) Co-récepteur de récepteur odorant
DK4088612T3 (da) Fastgørelsesanordning
DK4011339T3 (da) Stomianordning
MA42133A (fr) Modulateurs du ccr2
DK3680364T3 (da) Elektrolyseindretning
EP3069836C0 (fr) Dispositif de chevauchement
EP3580223A4 (fr) Modulateurs du récepteur des strogènes de benzothiophène
MA52555A (fr) Modulateurs du récepteur des oestrogènes
EP3565543A4 (fr) Modulateurs du récepteur opioïde de type mu
HUE062866T2 (hu) TREX-1 modulátorok
PT3568609T (pt) Dispositivo de fixação
EP3558318A4 (fr) Modulateurs des récepteurs nmda et utilisations de ceux-ci
EP3374386C0 (fr) Modulateurs du récepteur activé par protéase de type 2
IL247140A0 (en) Pyrazines modulators of gpr6
EP3532062A4 (fr) Modulateurs de ror-gamma
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
ME03379B (fr) Modulateurs allostériques positifs du récepteur muscarinique m1